Integrated Multidisciplinary Brain Metastasis Care Reduces Patient Visits and Shortens Time to Adjuvant Irradiation

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Nelson S. Moss

Consulting or Advisory Role: AstraZeneca

Research Funding: GT Medical Technologies (Inst)

Samantha Brown

Research Funding: AACR (Inst)

Justin Chen

Stock and Other Ownership Interests: MindMed, Moderna Therapeutics, Tonix Pharmaceuticals, Ocugen, Ocuphire Pharma, Innerscope Hearing Technologies, Heat Biologics

Brandon S. Imber

Honoraria: GT Medical Technologies

Luke Pike

Stock and Other Ownership Interests: Clovis Oncology, Schrodinger, Novavax

Consulting or Advisory Role: Blackstone, Deerfield Management, Third Rock Ventures, Aviko, Monograph Capital, Roivant, Galera Therapeutics, Dynamo Therapeutics, Myst Therapeutics, Turnstone Bio, Best Doctors Inc

Katherine S. Panageas

Stock and Other Ownership Interests: AstraZeneca, Pfizer, Sunesis Pharmaceuticals

Cameron Brennan

Stock and Other Ownership Interests: AVEO

Patents, Royalties, Other Intellectual Property: Co-inventor on patents licensed through Memorial Sloan Kettering to Elucida Oncology

Viviane Tabar

Stock and Other Ownership Interests: BlueRock Therapeutics (I)

Honoraria: BlueRock Therapeutics (I)

Consulting or Advisory Role: BlueRock Therapeutics (I)

Research Funding: BlueRock Therapeutics (I)

Patents, Royalties, Other Intellectual Property: BlueRock Therapeutics (I)

Travel, Accommodations, Expenses: BlueRock Therapeutics (I)

Kathryn Beal

Stock and Other Ownership Interests: MMT (I)

No other potential conflicts of interest were reported.